NOVELTY - Efficiently providing a composition with high amounts of omega-3 phospholipids comprises: contacting immature fish roe with a polar solvent; extracting a lipid fraction from the immature fish roe, to provide a primarily polar lipid fraction comprising omega-3 phospholipids; and removing the solvent from the lipid fraction, to provide a solid polar lipid composition comprising omega-3 phospholipids, where at least 40% of the total fatty acids of the lipid fraction are omega-3 fatty acids, and the fatty acids of the composition comprise docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)    USE - The lipid composition is useful in oral delivery vehicle, functional food product (claimed) or dietary supplements. The phospholipid composition is useful for treating or inhibiting diseases and conditions such as high blood triglycerides, high cholesterol, inflammation, hypertension, metabolic syndrome, obesity, cognitivedecline, and memory loss. The method is useful for treating or preventing a cardiometabolic disorder/metabolic syndrome such as e.g. atherosclerosis, arteriosclerosis, coronary heart (carotid artery) disease, acute coronary syndrome, valvular heart disease, aortic and mitral valve disorders, arrhythmia/atrial fibrillation, cardiomyopathy and heart failure, angina pectoris, acute myocardial infarction, orthostatic hypotension, shock, embolism (pulmonary and venous), endocarditis, diseases of arteries, the aorta and its branches, disorders of the peripheral vascular system (peripheral arterial disease), Kawasaki disease, congenital heart disease (cardiovascular defects) and stroke (cerebrovascular disease), dyslipidemia, hypertriglyceridemia, hypertension, heart failure, cardiac arrhythmias, low HDL levels, high LDL levels, stable angina, coronary heart disease, acute myocardial infarction, secondary prevention of myocardial infarction, cardiomyopathy, endocarditis, type 2 diabetes, insulin resistance, impaired glucose tolerance, hypercholesterolemia, hyperlipidemia, hyperlipoproteinemia, chronic kidney disease, intermittent claudication, hyperphosphatemia, omega-3 deficiency, phospholipid deficiency, carotid atherosclerosis, peripheral arterial disease, diabetic nephropathy, hypercholesterolemia in HIV infection, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, arterial occlusive diseases, cerebral atherosclerosis, arteriosclerosis, cerebrovascular disorders, myocardial ischemia, coagulopathies leading to thrombus formation in a vessel, or diabetic autonomic neuropathy, depression, allergic diseases, acute cardiovascular events, muscle wasting diseases, and cancer and cachexia. Test details described but no results given.    ADVANTAGE - The lipid composition is stable to oxidation. The process safely obtains omega-3 phospholipids with high stability, improved solubility, absorbability and bio-efficacy in an environmentally friendly manner.    DETAILED DESCRIPTION - Efficiently providing a composition with high amounts of omega-3 phospholipids comprises: contacting immature fish roe with a polar solvent; extracting a lipid fraction from the immature fish roe, to provide a primarily polar lipid fraction comprising omega-3 phospholipids; and removing the solvent from the lipid fraction, to provide a solid polar lipid composition comprising omega-3 phospholipids, where at least 40% of the total fatty acids of the lipid fraction are omega-3 fatty acids, the fatty acids of the composition comprise docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and the ratio of DHA to EPA is at least 1.3:1. INDEPENDENT CLAIMS are included for:    (1) a composition prepared by the process;    (2) a lipid composition comprising a phospholipid wax (20-90 wt.%) and a carrier oil (10-90 wt.%), where the phospholipid wax comprises phosphatidylcholine (at least 35 wt.%), fatty acids (40-55 wt.%) of the phospholipid wax such as DHA and EPA, and the ratio of DHA to EPA is at least 1.5:1, the carrier oil comprises mono-, di- or triglycerides, fatty acid ethyl esters, free fatty acids, and/or phospholipids, where the combination of the phospholipid wax and the carrier oil forms a viscous fluid oil;    (3) an oral delivery vehicle or functional food product comprising the lipid composition;    (4) a method comprising administering a lipid composition to a subject to provide a phospholipid composition to the subject, where the ratio of DHA to EPA is at least 2:1;    (5) a solid phospholipid-rich lipid composition comprising phospholipids (more than 60%), where the 40-55 wt.% the fatty acids of the phospholipids are DHA and EPA is 1.5:1-3.5:1;    (6) a process of producing a solid phospholipid-rich lipid composition with a high content of DHA comprising contacting a fish or fish by-product with a polar solvent to form a mixture with a polar solvent fraction, and removing the solvent from the polar solvent fraction to provide a solid phospholipid rich lipid composition comprising greater than 60% phospholipids; and    (7) an emulsion comprising water and a solid polar lipid composition prepared by the process, where the phospholipid wax composition increases the oxidative stability of the emulsion.